Pick These 5 Bargain Stocks With Exciting EV-to-EBITDA Ratios

The article highlights EV-to-EBITDA as a preferred valuation screen over P/E and identifies five stocks that passed its bargain criteria: FAF, AMN, CVE, PCG and SAFE. It notes favorable analyst revisions and expected 2026 EPS growth for each name, including FAF (+11.1%), AMN (+41.9%), CVE (+48.1%) and PCG (+10.0%). The piece is primarily educational and screening-focused, so the near-term market impact is limited.

Analysis

This screen is less a pure value list than a refinancing/liquidity quality filter. The common thread is that these names can look optically cheap on equity multiples while still carrying enough enterprise-level support to avoid classic value traps; that matters because the market is increasingly punishing balance-sheet fragility and rewarding cash-flow visibility. In that sense, the biggest second-order winner may be lenders and bondholders in these sectors, since equity upside here is likely to come from multiple compression reversing only after the market gains confidence in earnings durability.

The dispersion in catalyst quality is meaningful. AMN is the cleanest earnings-momentum story: staffing demand is cyclical, but the estimate revisions imply consensus may still be underestimating margin normalization if labor demand stabilizes into 2026. CVE is the most macro-beta levered name; if crude stays range-bound or firm, the earnings revisions can keep expanding, but the trade breaks quickly on a $5-10/bbl commodity drawdown. FAF and PCG are more rate/regulatory-sensitive; they can grind higher, but both are vulnerable to any rise in long-end yields or a reset in risk premium, which would hit the exact valuation framework the screen is celebrating.

The contrarian point is that low EV/EBITDA is not uniformly cheap when the denominator is near peak earnings. That is most relevant for CVE and AMN, where consensus may be extrapolating favorable conditions too far forward. By contrast, SAFE may be the most mispriced on duration: if rates begin to fall, the stock can re-rate faster than the earnings revisions alone would suggest because real estate capital values, not just reported earnings, improve. The market is likely underpricing how much of the upside here is really a factor trade in rates, commodities, and credit spreads rather than a simple stock-picking value story.

Key Decisions for Investors

• Long AMN vs. short a healthcare services basket for 3-6 months: best risk/reward if labor demand stabilizes and estimate revisions continue; cut if revisions stall for two consecutive quarters.
• Long CVE on weakness only, with a 1-2 quarter horizon: attractive if crude stays constructive, but size smaller than usual because the trade is highly dependent on commodity persistence.
• Pair long FAF / short a mortgage-sensitive financial with weaker earnings momentum for 6 months: FAF has cleaner upgrade momentum, but the position should be hedged because higher-for-longer rates would cap multiple expansion.
• Avoid chasing PCG here; use it only as a defensive utility-style hold if you want earnings stability, but the catalyst path is slow and upside is likely lower than the screen implies.
• Watch SAFE as a rates-down call option; initiate only if Treasury yields roll over, since the re-rating could be sharper than the reported earnings growth suggests.